Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/73780
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAl-Dasooqi, N.-
dc.contributor.authorGibson, R.-
dc.contributor.authorBowen, J.-
dc.contributor.authorKeefe, D.-
dc.contributor.editorWhitehouse, D.-
dc.contributor.editorRapley, R.-
dc.date.issued2012-
dc.identifier.citationMolecular and Cellular Therapeutics, 2012 / Whitehouse, D., Rapley, R. (ed./s), pp.69-102-
dc.identifier.isbn0470748141-
dc.identifier.isbn9780470748145-
dc.identifier.urihttp://hdl.handle.net/2440/73780-
dc.description.abstractHER2 (v-erb-b2 erythroblastic leukemia viral oncogene) is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. Since the discovery of a role for HER2 and other EGF receptors in the development and progression of cancer, they have become targets for a number of targeted anti-cancer drugs. These drugs have proven to be effective in treating and managing a range of cancers, however, recent observations in the clinic have suggested that their administration causes many toxicities, including gastrointestinal toxicity. Drugs with HER2 inhibitory activity fall into two categories; the monoclonal antibodies and small molecule tyrosine kinase inhibitors. Both of these drug classes have been shown to induce symptoms consistent of mucositis development; including nausea and vomiting, diarrhoea and abdominal pain. However, to date, limited studies have been carried out to justify the source of these toxicities. This chapter summarises our current knowledge of the toxicities associated with commonly used HER2 targeted therapy drugs, the role of HER2 in cancer and the healthy gastrointestinal tract and the possible mechanisms by which drugs with HER2 inhibitory activity can induce gastrointestinal damage and possibly mucositis in patients. © 2012 John Wiley & Sons, Ltd.-
dc.description.statementofresponsibilityNoor Al-Dasooqi, Rachel J. Gibson, Joanne M. Bowen and Dorothy M. Keefe-
dc.description.urihttp://trove.nla.gov.au/work/157109184?q=9780470748145&c=book&sort=holdings+desc&_=1351552618126&versionId=171262795-
dc.language.isoen-
dc.publisherWiley-
dc.source.urihttp://dx.doi.org/10.1002/9781119967309.ch3-
dc.titleHER2 targeted therapy-induced gastrointestinal toxicity: from the clinical experience to possible molecular mechanisms-
dc.typeBook chapter-
dc.identifier.doi10.1002/9781119967309.ch3-
dc.publisher.placeUnited Kingdom-
pubs.publication-statusPublished-
dc.identifier.orcidGibson, R. [0000-0002-4796-1621]-
dc.identifier.orcidBowen, J. [0000-0003-0876-0031]-
dc.identifier.orcidKeefe, D. [0000-0001-9377-431X]-
Appears in Collections:Aurora harvest 4
Medical Sciences publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.